Incidence of pulmonary complications with prophylactic use of high-flow nasal cannula after pediatric cardiac surgery

Incidence of pulmonary complications with prophylactic use of high-flow nasal cannula after pediatric cardiac surgery - Prophylactic high-flow nasal cannula study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025494

Enrollment

100

Registered

2017-04-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients after pediatric cardiac surgery

Interventions

HFNC (Optiflow

Fisher and Paykel Healthcare Ltd, Auckland, New Zealand) therapy is prophylactically commenced just after extubation with 2L / kg / min of flow, 37 degrees of temperature with humidifier and adequate

94%. We choose nasal cannula size according to child&#39

s weight and nasal size. HFNC will be continued for 24-hours after extubation if intolerance does not occurred. If patients are not tolerant to HFNC treatment with flow of 2L / kg / min, we reduce

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients after pediatric cardiac surgery (Total repair)

Exclusion criteria

Exclusion criteria: cyanosis congenital heart disease tracheotomy facial deformity unplanned extubation

Design outcomes

Primary

Measure	Time frame
The primary outcome is the incidences of PPCs within 48 hours after extubation. PPCs are defined as the combination of atelectasis diagnosed by chest radiography and acute respiratory failure. Radiologist measures atelectasis by chest radiography at 1 and 2 postextubation days. Investigator diagnoses ARF at 1 and 2 postextubation day. Definition of respiratory failure 1 Increased respiratory rate (RR) for their age+The use of accessory respiratory muscle RR>50 breath per minute (<1 year old) RR>40 breath per minute (1-4 years ol0 2 Hypoxemic acute respiratory failure (type 1) PaO2<60 mmHg SaO2<90% (with FiO2>0.5) 3 Hypercapnic acute respiratory failure (type 2) pH<7.35 with PaCO2>50 mmHg 4 Mix form of acute respiratory failure Prophylactic use of HFNC therapy might have the potential to reduce the incidence of PPCs following extubation after pediatric cardiac surgery. To investigate this hypothesis, we set PPCs incidence less than 10% as a threshold of a effectiveness of prophylactic HFNC therapy on the basis of the reintubation rate in children underwent cardiac surgery in previous reports (6 to 9%)	—

Measure

Time frame

The primary outcome is the incidences of PPCs within 48 hours after extubation. PPCs are defined as the combination of atelectasis diagnosed by chest radiography and acute respiratory failure. Radiologist measures atelectasis by chest radiography at 1 and 2 postextubation days. Investigator diagnoses ARF at 1 and 2 postextubation day. Definition of respiratory failure 1 Increased respiratory rate (RR) for their age+The use of accessory respiratory muscle RR>50 breath per minute (<1 year old) RR>40 breath per minute (1-4 years ol0 2 Hypoxemic acute respiratory failure (type 1) PaO2<60 mmHg SaO2<90% (with FiO2>0.5) 3 Hypercapnic acute respiratory failure (type 2) pH<7.35 with PaCO2>50 mmHg 4 Mix form of acute respiratory failure Prophylactic use of HFNC therapy might have the potential to reduce the incidence of PPCs following extubation after pediatric cardiac surgery. To investigate this hypothesis, we set PPCs incidence less than 10% as a threshold of a effectiveness of prophylactic HFNC therapy on the basis of the reintubation rate in children underwent cardiac surgery in previous reports (6 to 9%)

—

Secondary

Measure	Time frame
Reintubation less than 48hours Completion rate of 24-hours HFNC therapy Length of ICU stay PaO2 / FiO2 (post-extubation periods) High-flow nasal cannula related adverse events	—

Countries

Japan

Contacts

Public ContactNaohiro Shioji

Okayama university hospital department of critical care

snaohiro116@gmail.com086-235-7778

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026